Brandes Investment Partners Adds $41M in Grifols, S.A. ($GRFS)

Brandes Investment Partners has increased its stake in Grifols, S.A. (NasdaqGS: GRFS), according to its latest Form 13F filing with the SEC. The firm added 5,379,491 shares during the reporting period, boosting its total holdings to 36,333,714 shares. This represents a 17.4% increase, with the position now valued at approximately $277.6 million.

What Changed in Brandes Investment Partners' Grifols Position

Brandes Investment Partners significantly boosted its investment in Grifols, S.A., adding over 5.3 million shares. As of the filing, the firm's total position stands at 36.33 million shares, up from 30.95 million shares previously. This increase reflects a 17.4% growth in their stake, with the total value of the position now at $277.6 million.

Other Institutional Activity in Grifols

Several other institutional investors have also made moves in Grifols recently. Permian Investment Partners increased its holdings by 1,164,417 shares, ending with 19,354,679 shares valued at about $155.2 million. Meanwhile, Black Creek Investment Management reduced its position by 870,675 shares, bringing its total to 8,386,452 shares, worth approximately $67.3 million. Millennium Management also cut its holdings by 2,116,623 shares, now holding 5,005,532 shares valued at $40.1 million.

Grifols, S.A. Stock Snapshot

Shares of Grifols, S.A. (NasdaqGS: GRFS) recently traded near $7.64. The company has a market capitalization of about $5.2 billion, with a P/E ratio of 10.91 and a forward P/E of 5.29. Grifols' stock has seen a 52-week low of $7.26 and a high of $11.14. The 50-day moving average stands at $8.01, while the 200-day moving average is $8.82. The company maintains a current ratio of 2.47 and a quick ratio of 0.78, with a debt-to-equity ratio of 123.22.

Recent Earnings

Grifols reported revenue of approximately $7.44 billion, although it experienced a revenue decline of 4.8%. The company posted a net margin of 5.58% and a return on equity of 6.13%. Investors can look forward to the next earnings release scheduled for July 29, 2026.

Dividend

Grifols offers an annual dividend rate of $0.18 per share, resulting in a yield of 2.3%. The dividend payout ratio is 24.7%, indicating a sustainable distribution relative to its earnings.

Analysts Set New Price Targets

Analysts have recently weighed in on Grifols, with JP Morgan maintaining a 'hold' rating and setting a price target of $10 as of December 8, 2025. The consensus among analysts is a target mean price of $10.87, based on two opinions.

About Grifols, S.A.

Grifols, S.A., headquartered in Barcelona, Spain, is a healthcare company specializing in plasma-derived medicines. It operates through several segments, including Biopharma, Diagnostics, and Bio Supplies, providing treatments for various medical conditions. The company also offers diagnostic testing equipment and transfusion medicine services. Founded in 1909, Grifols employs approximately 25,000 people globally.

Bottom Line

Brandes Investment Partners' increased stake in Grifols, S.A. underscores the firm's confidence in the company. Investors should note that 13F filings are historical snapshots and may not reflect current positions. Grifols remains a significant player in the healthcare sector, with a variety of institutional investors adjusting their positions.